OPKO Health (NASDAQ:OPK) Raised to Strong-Buy at Zacks Research

OPKO Health (NASDAQ:OPK) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday, Zacks reports.

A number of other research firms have also recently commented on OPK. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, August 13th. Wall Street Zen raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of OPKO Health in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $1.55.

OPKO Health Trading Down 0.6%

OPK opened at $1.62 on Monday. OPKO Health has a 12 month low of $0.98 and a 12 month high of $1.75. The stock has a fifty day moving average price of $1.48 and a 200-day moving average price of $1.35. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -18.00 and a beta of 1.50. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.07. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The business had revenue of $163.58 million during the quarter, compared to the consensus estimate of $131.23 million. During the same period in the previous year, the company posted ($0.19) earnings per share. The firm’s revenue was up 4.3% on a year-over-year basis. As a group, equities research analysts anticipate that OPKO Health will post -0.23 earnings per share for the current fiscal year.

Institutional Trading of OPKO Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Securities LLC acquired a new position in OPKO Health in the 2nd quarter worth approximately $27,000. World Investment Advisors lifted its stake in OPKO Health by 63.8% during the 4th quarter. World Investment Advisors now owns 66,520 shares of the biotechnology company’s stock valued at $84,000 after acquiring an additional 25,902 shares during the period. Apella Capital LLC purchased a new stake in shares of OPKO Health in the 1st quarter valued at $34,000. EP Wealth Advisors LLC acquired a new stake in shares of OPKO Health in the second quarter worth $45,000. Finally, Diversify Advisory Services LLC purchased a new position in shares of OPKO Health during the second quarter worth $37,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Its diagnostics business includes BioReference Laboratories, which provides clinical laboratory testing and specialty diagnostic services in the United States, and the 4Kscore test, a blood-based test designed to help assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical activities include products and development programs in areas such as endocrinology, nephrology, and other specialty-care markets.